drugset / Trial / NCT02553824

FDA Approved Medication to Reduce Binge Eating and/or Purging

NCT02553824

Phase 1 Completed 22 enrolled Stanford University
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.

Timeline

Start
2015-10-30
Primary completion
2017-02-23
Completion
2017-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentermine Small molecule 15 mg
Subject Topiramate Small molecule 92 mg